Vaxirab N Injection
Rabies Vaccine (Human) BP
Zydus Pharmaceuticals
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Available as:
Indications
Vaxirab N Injection is used for:
To prevent Rabies virus
Adult Dose
Intramuscular
Active immunisation against rabies
Adult: 1 ml for adults:
a) Pre-exposure immunization Primary-vaccination: According to the WHO recommendations 1 injection by the intramuscular route on days D0, D7, D21 or D28, followed by a booster dose one year later. Boosters Thereafter, one injection every 5 years or when the titre is found to be less than 0.5 I.U./ml.
b) Post-exposure treatment Intramuscular schedule:
Non-vaccinated individuals: Treatment consists of 5 injections. Intramuscular injections to be given on Day 0, D3, D7, D14 and D28 subsequent to contact with an animal confirmed or suspected of being rabid. In case of severe (WHO category 3) wounds, immunoglobulin should be administered as soon as possible.
Fully vaccinated individuals: If vaccine administered in less than 5 years of exposure (cell culture rabies vaccine): 2 injections on D0, D3. If vaccine administered in more than 5 years of exposure or incomplete vaccination: 5 injections on D0, D3, D7, D14 and D28 with administration of immunoglobulin if required. Post exposure vaccination must be administered on the basis of severity under medical supervision.
Child Dose
Intramuscular
Child:
1 ml for children:
a) Pre-exposure immunization Primary-vaccination: According to the WHO recommendations 1 injection by the intramuscular route on days D0, D7, D21 or D28, followed by a booster dose one year later. Boosters Thereafter, one injection every 5 years or when the titre is found to be less than 0.5 I.U./ml.
b) Post-exposure treatment Intramuscular schedule:
Non-vaccinated individuals: Treatment consists of 5 injections. Intramuscular injections to be given on Day 0, D3, D7, D14 and D28 subsequent to contact with an animal confirmed or suspected of being rabid. In case of severe (WHO category 3) wounds, immunoglobulin should be administered as soon as possible.
Fully vaccinated individuals: If vaccine administered in less than 5 years of exposure (cell culture rabies vaccine): 2 injections on D0, D3. If vaccine administered in more than 5 years of exposure or incomplete vaccination: 5 injections on D0, D3, D7, D14 and D28 with administration of immunoglobulin if required. Post exposure vaccination must be administered on the basis of severity under medical supervision.
Renal Dose
Administration
Contra Indications
Pre-exposure
Severe fever, febrile infection, acute disease, progressive chronic diseases. Known hypersensitivity reactions to rabies vaccine or any of its components.
Post-exposure
No contraindication to post-exposure treatment, because rabies is lethal disease, any contraindication to exposure, treatment should be considered carefully before disqualifying an individual for anti-rabies treatment.
Precautions
Possibility of immune complex reaction 2-21 days after booster doses of HDCV (Human diploid cell cultures rabies vaccine); symptoms include arthralgia, arthritis, nausea, malaise, angioedema, fever and vomiting. Caution when used in patients with bleeding disorders, patients on anticoagulant treatment, severely immunocompromised patients. Not to be used in patients with confirmed diagnosis of rabies. Postexposure prophylaxis may be started regardless of the length of time from likely exposure, as long as clinical signs of rabies infection are not present. Pregnancy
Lactation: if exposure to rabies suspected, nursing a baby is not a priority as far as immunization is concerned
Pregnancy-Lactation
Interactions
Concurrent use with immunosuppressants may reduce the efficacy of vaccines.
Adverse Effects
Side effects of Rabies Vaccine (Human) BP :
>10%
Injection site pain, soreness, swelling, erythema, itching, burning (30-74%),N/V (5-40%),Abdominal pain (5-40%),Diarrhea (5-40%),Headache (5-40%),Fatigue (5-40%),Localized enlarged lymph nodes sore throat (5-40%),Low grade fever (5-40%),Chills (5-40%),Muscle ache (5-40%),Dizziness (5-40%),Malaise (5-40%)
Mechanism of Action
Rabies vaccine is an inactivated virus vaccine that is used for active immunisation against rabies. It can be used for pre- and post-exposure immunisation. For post-exposure immunisation, it is often used in conjunction with rabies immunoglobulins as it takes about 7-10 days for the specific antibodies to develop.
Note
Vaxirab N Injection manufactured by Zydus Pharmaceuticals. Its generic name is Rabies Vaccine (Human) BP. Vaxirab N is availble in Nepal.
Farmaco Nepal drug index information on Vaxirab N Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.